

Memorandum of Understanding for the French-Swedish Partnership in Precision Medicine

between

the French National Alliance for Life Sciences and Health - Aviesan

and

Genomic Medicine Sweden

The *Institut National de la Santé et de la Recherche Médicale* (Inserm), with registered office in Paris (France) represented by its Chairman and CEO, Gilles Bloch, acting in the name and on behalf of the members of the French National Alliance for Life Sciences and Health, hereinafter referred to as “Aviesan”

And

Genomic Medicine Sweden, GMS, represented by Gunilla Bodelsson, Skåne Regional Council, Sweden, acting in behalf of the partners in GMS (as set out in Appendix 1)

jointly referred to as “the Parties”,

Considering

- That Aviesan, the French National Alliance for Life Sciences, is the umbrella organisation in France which notably leads and delivers the 2025 French Genomic Medicine Initiative, a national initiative which aims to position France as a leading country in the area of personalised and precision medicine, to prepare for the integration of genomic medicine into the healthcare pathway and to establish a national genomic medicine framework capable of driving scientific and technological innovation;
- That GMS is the Swedish national initiative in genomic-based precision medicine aimed at ensuring that patients in Sweden have equal access to cost-effective genetic analysis to facilitate improved diagnostics and thereby more personalised care, treatment and prevention. GMS will build an infrastructure for the secure sharing of data between regional health authorities and with academia and private sector. GMS is one of the national initiatives that will play a vital role in achieving Sweden’s stated ambition of becoming a leading life science nation.
- That France and Sweden share the ambition of building and operating advanced and competitive Genomic Healthcare and Research ecosystems. They have similar and complementary initiatives representing two ambitious and large public commitments to create infrastructures delivering a global leading 21st Century genomic medicine service. This common vision for genomics and our shared national attributes makes it timely to consider how a partnership between Genomic Medicine Sweden and Aviesan could accelerate genomic healthcare.

- That as part of this strategic alliance, the Parties will share experience of implementation of genomics and precision medicine approaches in healthcare and mutually demonstrate the clinical utility of genomic medicine for rare diseases, cancer and other common diseases.
- That both initiatives recognise the opportunities and potential for synergy from such a joint strategic research and development programme, which is the focus of this proposal. Together, the parties can more comprehensively address specific outstanding academic research, medical research, data analysis and bioinformatic questions of outmost importance in genomics and precision medicine and form a partnership presenting opportunities for synergy from the existing critical mass of talent in both nations. This will ensure that these programmes create an enduring collaboration that will deliver leading-edge genomic healthcare for both France and Sweden with global ramifications.

With the objective of

Building common approaches for implementation of genomic medicine/precision medicine in healthcare, including GDPR-compliant data sharing. This strategic alliance will promote faster and more successful advances by combining the attributes and research endeavour of both Nations and their respective research and healthcare infrastructure, hereby concluded this Memorandum of Understanding (hereinafter referred to as “MoU”):

Article 1: Collaborative activities

The main collaborative activities promoted under this MoU concern:

1. Advancement of precision diagnostics/precision medicine:
 - 1.1 Joint work on standardization of assays for precision diagnostics, including bioinformatic analyses
 - 1.2 Exchange experience and expertise on development of national informatics platform for secure storage and sharing of data
 - 1.3 Data protection & ethics issues in order to remain GDPR-compliant
 - 1.4 Share data in specific studies that have ethical approval for cross-border data sharing
 - 1.5 Exchange experience how to develop clinical decision support systems and knowledge databases.
2. Develop education activities for the healthcare profession, general public and patient organizations.
3. Identifying third-party funding sources for joint collaborative studies.

Article 2: Principles

The principles promoted under this MoU are:

- 2.1 Formation of a joint Aviesan and Genomic Medicine Sweden working group with identified leaders from Aviesan and Genomic Medicine Sweden. The role of the working group will be to identify key elements that would be enriched by the Parties, ensuring that channels of communication are created and remain active.
- 2.2 Building of appropriate links between the Parties to determine the scope of the collaboration, develop a roadmap and deliverables.
- 2.3 The exchange of knowledge and research standard procedures between Genomic Medicine Sweden and the Collector Analyser of Data (CAD), for Aviesan.
- 2.4 Exchange of scientific staff by means of short secondments of up to 3 months, for the purpose of advancing techniques in the fields of interest, subject to mutually agreeable terms formalising a secondment.
- 2.5 Organization of joint scientific events and activities for the purpose of promoting transnational collaboration and creating links between genomics specialists of both Parties.
- 2.6 The fields of science in which the Parties will collaborate are flexible and based on mutual interest, as agreed in writing from time to time.
- 2.7 Each Party will bear the costs relating to its contribution in the collaborative activities.
- 2.8 Scientists, visiting one of the Parties as part of the collaborative activities, will abide by all relevant rules and procedures of the host Party, including those relating to safety, office administration and travel.
- 2.9 The implementation of this MoU will be subject to specific agreements mutually discussed and agreed upon in writing by authorized representatives of both Parties prior to the initiation of the activity. These specific agreements shall govern, as the case maybe, intellectual property rights, confidentiality, liability, publication, communication, finance and other appropriate matters for implementation of the cooperative activities under this MoU.

Article 3: Questions and Consultation

In the event that questions should arise concerning the interpretation of the provisions of the MoU, or problems should be caused by matters not prescribed herein, both Parties will consult with each other and conclude a mutually acceptable solution.

Article 4: Duration and Amendment

- 4.1 This MoU will come into effect upon signature by both Parties and remain valid for a period of three years thereafter, unless either Party chooses to terminate it sooner having first given six (6) months written notice of this intention to the other Party.
- 4.2 This MoU may be amended or renewed by the mutual written agreement of both Parties.

Each Party will sign two identical copies of this MoU, and will retain one copy each.

Aviesan




Gilles Bloch

Chairman & CEO Inserm

President Aviesan

Date, Place: 14.10.2021
Stockholm

Genomic Medicine Sweden




Gunilla Bodelsson

Representative Skåne Regional Council

Member of GMS Steering Board

Date, Place: 21/10/08, Lund

Genomic Medicine Sweden



Richard Rosenquist Brandell

Director Genomic Medicine Sweden

Date, Place: 19 Oct 2021
Stockholm